Cargando…

Improved outcomes of UM171–expanded cord blood transplantation compared with other graft sources: real-world evidence

Cord blood (CB) transplantation is hampered by low cell dose and high nonrelapse mortality (NRM). A phase 1-2 trial of UM171-expanded CB transplants demonstrated safety and favorable preliminary efficacy. The aim of the current analysis was to retrospectively compare results of the phase 1-2 trial w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Sandra, Bambace, Nadia, Ahmad, Imran, Roy, Jean, Tang, Xiaoying, Zhang, Mei-Jie, Burns, Linda, Barabé, Frédéric, Bernard, Léa, Delisle, Jean-Sébastien, Kiss, Thomas, Lachance, Silvy, Roy, Denis-Claude, Veilleux, Olivier, Sauvageau, Guy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539875/ https://www.ncbi.nlm.nih.gov/pubmed/37467030 http://dx.doi.org/10.1182/bloodadvances.2023010599

Ejemplares similares

Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Kadri, Yasmine, et al.
Publicado: (2022)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

UM171 induces a homeostatic inflammatory-detoxification response supporting human HSC self-renewal
por: Chagraoui, Jalila, et al.
Publicado: (2019)

UM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells
por: Ngom, Mor, et al.
Publicado: (2018)

UM171 expands distinct types of myeloid and NK progenitors from human pluripotent stem cells
por: Mesquitta, Walatta-Tseyon, et al.
Publicado: (2019)

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
por: Locatelli, Franco, et al.
Publicado: (2022)

CD14(+)/CD31(+) monocytes expanded by UM171 correct hemophilia A in zebrafish upon lentiviral gene transfer of factor VIII
por: Elnaggar, Muhammad, et al.
Publicado: (2022)

More Haste, Less Speed: Could Public–Private Partnerships Advance Cellular Immunotherapies?
por: Bubela, Tania, et al.
Publicado: (2017)

External validation of the PEGeD diagnostic algorithm for suspected pulmonary embolism in an independent cohort
por: Robert-Ebadi, Helia, et al.
Publicado: (2022)

UM171 cooperates with PIM1 inhibitors to restrict HSC expansion markers and suppress leukemia progression
por: Hu, Anling, et al.
Publicado: (2022)

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022)

Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity
por: Courjon, Johan, et al.
Publicado: (2021)

UM171A-induced ROS promote antigen cross-presentation of immunogenic peptides by bone marrow-derived mesenchymal stromal cells
por: Salame, Natasha, et al.
Publicado: (2022)

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome
por: Jacobson, Caron A., et al.
Publicado: (2023)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
por: Sobas, Marta, et al.
Publicado: (2022)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
por: Freeman, Sylvie D., et al.
Publicado: (2023)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
por: Cohen, Adam D., et al.
Publicado: (2023)

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
por: Lambert, Juliette, et al.
Publicado: (2021)

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
por: Fenaux, Pierre, et al.
Publicado: (2023)

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
por: Elsawy, Mahmoud, et al.
Publicado: (2022)

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
por: Michallet, Anne-Sophie, et al.
Publicado: (2023)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth
por: Deshpande, Suprit, et al.
Publicado: (2023)

High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya
por: McAuley, Charlotte F., et al.
Publicado: (2010)

Reduced prevalence of SARS-CoV-2 infection in ABO blood group O
por: Barnkob, Mike Bogetofte, et al.
Publicado: (2020)

The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19
por: Hoiland, Ryan L., et al.
Publicado: (2020)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)

When CLL meets COVID-19
por: Montserrat, Emili
Publicado: (2020)

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
por: Mato, Anthony R., et al.
Publicado: (2020)

COVID-19 and SCA: an old friend comes to the rescue
por: Novelli, Enrico M.
Publicado: (2020)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection
por: Minniti, Caterina P., et al.
Publicado: (2021)

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

COVID-19, plasma, and hypogammaglobulinemia
por: Murphy, Michael F., et al.
Publicado: (2020)

Under COVID of the night
por: Sekeres, Mikkael A.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lkabk0pt9i6m835pj8mbb4dtbs